A1 Refereed original research article in a scientific journal

Pubertal development and hypogonadism in males with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy: a retrospective study




AuthorsTräskilä Emilia, Holopainen Elina, Mäyränpää Mikko I., Toppari Jorma, Mäkitie Outi, Laakso Saila

PublisherBioScientifica Ltd.

Publication year2023

JournalEuropean Journal of Endocrinology

Journal name in sourceEuropean Journal of Endocrinology

Volume188

Issue4

eISSN1479-683X

DOIhttps://doi.org/10.1093/ejendo/lvad034

Web address https://doi.org/10.1093/ejendo/lvad034

Self-archived copy’s web addresshttps://research.utu.fi/converis/portal/detail/Publication/179813667


Abstract

The aim of this study was to describe the course of puberty and hypogonadism in males with autoimmune polyendocrinopathy–candidiasis–ectodermal dystrophy (APECED) in a Finnish APECED cohort followed up between 1970 and 2020. Anthropometry, testicular volumes and FSH, LH, and testosterone concentrations were analyzed retrospectively. Forty-three males were followed up until the median age of 42.5 years (range, 16.2-74.8). All subjects fulfilled the clinical criteria for APECED. The median age at the onset of spontaneous puberty was 13.3 years (10.8-14.8). Testosterone medication was used to promote pubertal development from the median age of 14.9 years (13.5-15.7), for 0.7-3.3 years in 8 patients. The median adult height was 173.0 cm and differed from the mid-parental target height on average −1.3 SDS (P < .001). Hypogonadism was treated in 6 patients (14%). Azoospermia was found in 3 patients. Further studies are required to explore the role of the autoimmune regulator in sperm production and testicular insufficiency.


Downloadable publication

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2025-27-03 at 21:53